The association of diabetes and positive prostate biopsy in a US veteran population

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 1, 2012, Pages 70-74

  Moses, K A ^a,b,d   Utuama, O A ^c   Goodman, M ^c   Issa, M M ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cancer; diabetes mellitus; prostate biopsy

Indexed keywords

AGED; CARCINOGENESIS; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; UNITED STATES; VETERAN;

AGED; BIOPSY; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; VETERANS;

EID: 84857062048     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.40     Document Type: Review

References (34)

1. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010; 304: 649-656.
2. Young BA, Maynard C, Reiber G, Boyko EJ. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care 2003; 26: 495-501. (Pubitemid 36929081)
3. Twombly JG, Long Q, Zhu M, Wilson PW, Narayan KM, Fraser LA et al. Diabetes care in black and white veterans in the southeastern U.S. Diabetes Care 2010; 33: 958-963.
4. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24: 1936-1940. (Pubitemid 33716504)
5. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999; 10: 313-318. (Pubitemid 29187769)
6. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2: 307-314.
7. Rosenberg DJ, Neugut AI, Ahsan H, Shea S. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002; 20: 157-165. (Pubitemid 34205481)
8. Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002; 11: 125-128. (Pubitemid 34478428)
9. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009; 169: 937-945.
10. Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: populationbased case-control study. Br J Cancer 2004; 90: 2171-2175. (Pubitemid 38869725)
11. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998; 9: 3-9. (Pubitemid 28048654)
12. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152. (Pubitemid 40096789)
13. Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Mehrsai AR et al. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 2009; 69: 1744-1750.
14. Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sonksen PH et al. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin Endocrinol (Oxf) 1998; 49: 739-746. (Pubitemid 29009503)
15. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ et al. The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology 2011; 77: 137-141.
16. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE et al. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer 2011; 128: 440-446.
17. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34 (Suppl 1): S11-S61.
18. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793-803. (Pubitemid 23135479)
19. Abd TT, Goodman M, Hall J, Ritenour CW, Petros JA, Marshall FF et al. Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans. Urology 2011; 77: 541-547.
20. Issa MM, Zasada W, Ward K, Hall JA, Petros JA, Ritenour CW et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detect Prev 2006; 30: 269-275. (Pubitemid 44163057)
21. Moses KA, Abd TT, Goodman M, Hsiao W, Hall JA, Marshall FF et al. Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black Americans. J Urol 2009; 182: 2219-2225.
22. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128: 635-643.
23. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002; 102: 258-261. (Pubitemid 35222294)
24. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 1910-1917. (Pubitemid 32036921)
25. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004; 22: 3104-3112. (Pubitemid 41103723)
26. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 2008; 19: 703-710.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
28. Freedland SJ, Terris MK, Platz EA, Presti Jr JC. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 2005; 66: 108-113. (Pubitemid 41002197)
29. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality inmen with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047.
30. Jayachandran J, Aronson WJ, Terris MK, Presti Jr JC, Amling CL, Kane CJ et al. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev 2010; 19: 9-17.
31. Hong SK, Oh JJ, Byun SS, Hwang SI, Lee HJ, Choe G et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (>/=12)-core prostate biopsy. Prostate 2011 ( prostate).
32. Abdollah F, Briganti A, Suardi N, Gallina A, Capitanio U, Salonia A et al. Does diabetes mellitus increase the risk of highgrade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis 2011; 14: 74-78.
33. Moreira DM, Anderson T, Gerber L, Thomas JA, Banez LL, McKeever MG et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011; 22: 977-983.
34. Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW. Obese African-Americans with prostate cancer (T1c and a prostatespecific antigen, PSA, level of o10 ng/ml) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int 2010; 106: 1157-1160.